GlycoGenetics, Inc. is a glycobiology-centric early-phase target discovery company. We develop bioanalytical and genetic engineering tools to address the current obstacles in applying glycobiology for drug discovery. Our highly integrated technological platform allows us to decipher the complex glycocodes of human biology, and, in turn, allows us to discover new druggable glyco-target, to optimize glycosylation pathways for industrial application, to identify new disease biomarkers, and to develop new treatments for unmet medical needs.